NASDAQ Framework: MoonLake Immunotherapeutics
1: MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland. View Source2: MoonLake Immunotherapeutics AG is a clinical-stage biopharmaceutical company leveraging revolutionary Nanobody® technology to develop next-level medicines for immunologic diseases, including inflammatory skin and joint diseases. View Source
MoonLake Immunotherapeutics, founded in 2021 and headquartered in Zug, Switzerland, is a clinical-stage biopharmaceutical company focused on leveraging revolutionary Nanobody® technology to develop next-level medicines for immunologic diseases, including inflammatory skin and joint diseases such as hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis 345.
3: MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland. View Source4: MoonLake Immunotherapeutics AG is a clinical-stage biopharmaceutical company leveraging revolutionary Nanobody® technology to develop next-level medicines for immunologic diseases, including inflammatory skin and joint diseases. View Source5: MoonLake Immunotherapeutics is a clinical-stage biotechnology company engaged in leveraging Nanobody technology to develop next-level medicines for immunologic diseases, including inflammatory skin and joint diseases. View Source
6: Cathy Vass HR Business change & transformation expert. Board Advisor. Co-founder of @greenzebra business solutions ltd. Andrew Fox Vice President, Regulatory Affairs Dragos V. Budinschi Jorge Santos da Silva Founder & CEO at MoonLake Immunotherapeutics (Nasdaq: MLTX) View Source7: Insider Sell: CEO Santos da Silva Jorge Sells 123,615 Shares of MoonLake Immunotherapeutics (MLTX) View Source
LOW RISK
MoonLake Immunotherapeutics appears to be in a strong financial position. The company has received positive regulatory feedback from both the FDA and EMA on its Phase 3 programs for its Nanobody® in psoriatic arthritis and hidradenitis suppurativa 89. Additionally, the company has been actively participating in various high-profile conferences and has secured significant partnerships, such as the three-year technology partnership with Komodo Health 10. The stock has also received favorable ratings from multiple analysts, including an "Outperform" rating from Oppenheimer and Wolfe Research, and a "Buy" rating from Citigroup and Stifel 11. These factors suggest that MoonLake Immunotherapeutics is well-positioned to cover its costs and spending plans, indicating a low-risk financial situation.
MoonLake Immunotherapeutics appears to be in a strong financial position. The company has received positive regulatory feedback from both the FDA and EMA on its Phase 3 programs for its Nanobody® in psoriatic arthritis and hidradenitis suppurativa 89. Additionally, the company has been actively participating in various high-profile conferences and has secured significant partnerships, such as the three-year technology partnership with Komodo Health 10. The stock has also received favorable ratings from multiple analysts, including an "Outperform" rating from Oppenheimer and Wolfe Research, and a "Buy" rating from Citigroup and Stifel 11. These factors suggest that MoonLake Immunotherapeutics is well-positioned to cover its costs and spending plans, indicating a low-risk financial situation.
8: MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody® sonelokimab in Psoriatic Arthritis View Source9: MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody® sonelokimab (SLK) in Hidradenitis Suppurativa (HS) View Source10: MoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditions View Source11: Oppenheimer raised the price target for the MoonLake Immunotherapeutics (NASDAQ:MLTX) stock to “an Outperform”. The rating was released on June 25, 2024, according to finviz. The research report from Wolfe Research has initiated the stock to Outperform, with a price target set at $77. The stock was initiated by Citigroup, who disclosed in a research note on December 08, 2023, to Buy and set the price objective to $72. In their research brief published November 02, 2023, Stifel analysts initiated the MoonLake Immunotherapeutics stock to Buy with a price target of $74. View Source
NO
There is no evidence in the provided facts that MoonLake Immunotherapeutics is launching any new product offerings. The information primarily discusses ongoing clinical trials, regulatory feedback, and conference participation but does not mention the launch of new products.
There is no evidence in the provided facts that MoonLake Immunotherapeutics is launching any new product offerings. The information primarily discusses ongoing clinical trials, regulatory feedback, and conference participation but does not mention the launch of new products.
MoonLake Immunotherapeutics has a robust product roadmap and expansion strategy for 2024 through to 2026, focusing on advancing its Nanobody® technology for treating inflammatory diseases. The company plans to initiate two Phase 3 trials under its new PsA program, named IZAR, in Q4 2024, with primary endpoint readouts expected by the end of 2026 12. Additionally, MoonLake has started its Phase 3 VELA program for hidradenitis suppurativa and is also preparing a Phase 3 program focused on adolescent HS 13. These initiatives are supported by positive regulatory feedback from both the FDA and EMA 14, and the company continues to engage in significant partnerships and high-profile conferences to further its research and development efforts 1516.
12: MoonLake Immunotherapeutics (NASDAQ: MLTX) 4.087 Follower:innen 1 Woche Diesen Beitrag melden For #media #investors: We are proud to be a corporate partner of Group for Research and Assessment of Psoriasis and Psoriatic Arthritis - GRAPPA, whose Annual Meeting and Trainee Symposium will take place in Seattle, US this week. Eva Cullen PhD and Naomi Attar, from our Medical Affairs team, will be attending the meeting and look forward to strengthening our partnership with GRAPPA as we strive toward our shared aims of enhancing research, diagnosis and treatment of psoriatic arthritis. We hope to see you there! If you are interested in arranging a meeting, please contact us at info@moonlaketx.com. #MoonLake #MLTX #PsA #Congress #Conference #HS #IL-17 #Seattle #GRAPPA2024 42 Gefällt mir Kommentieren Teilen MoonLake Immunotherapeutics (NASDAQ: MLTX) 4.087 Follower:innen 3 Wochen Diesen Beitrag melden For #media #investors: Our Medical Affairs team members Eva Cullen PhD, Naomi Attar and Sónia Guerra Gomes are attending IFPA’s 7th World Psoriasis & Psoriatic Arthritis Conference this week in Stockholm. MoonLake clinical trial data is set to be a highlight of the conference — with our abstract one of only six submissions selected by the IFPA scientific committee for an oral presentation. The presentation will report Week 12 multidomain outcomes in the PsA ARGO trial, with Prof. Joseph F Merola MD MMSc (Chair, Dermatology and Professor, Dermatology, Medicine & Rheumatology; UT Southwestern Medical Center, Dallas, TX, USA) as the presenting author. Morning plenary session, June 28, 2024 Main Auditorium, Stockholm Waterfront Congress Center We hope to see you there! If you are interested in arranging a meeting, please contact us at info@moonlaketx.com. #MoonLake #MLTX #PsA 69 Gefällt mir Kommentieren Teilen MoonLake Immunotherapeutics (NASDAQ: MLTX) 4.087 Follower:innen 4 Wochen Diesen Beitrag melden For #media #investors: We were thrilled to win Best Communication Award at the European Mediscience Awards 2024! This achievement would not have been possible without the support, encouragement, and inspiration from the incredible network of the MoonLake Communications Team! It’s also a testament to the power of teamwork and effective communication! Please find below our CFO, Matthias Bodenstedt with Patrícia Marques de Sousa, our Director of Corporate Affairs accompanied by Mary-Jane Elliott, Managing Partner, ICR Consilium, Nina Hossain and Michael White, Head of Life Sciences and Healthcare, HSBC Innovation Banking. Congratulations to all the other award winners and nominees! #MLTX #MoonLake #nanobody #HS #PsA #IL17A #IL17F 119 2 Kommentare Gefällt mir Kommentieren Teilen MoonLake Immunotherapeutics (NASDAQ: MLTX) 4.087 Follower:innen 4 Wochen Diesen Beitrag melden For #media #investors: Our CFO Matthias Bodenstedt is attending the Stifel Europe Healthcare Summit taking place in Lyon on 25-27 June. Contact us at ir@moonlaketx.com if you are interested in meeting. #MoonLake #MLTX #IL17A #IL17F #HS #PsA #nanobody 29 Gefällt mir Kommentieren Teilen MoonLake Immunotherapeutics (NASDAQ: MLTX) 4.087 Follower:innen 1 Monat Diesen Beitrag melden For #media #investors: Thank you EULAR - European Alliance of Associations for Rheumatology Congress for another engaging meeting! We thoroughly enjoyed hearing about the latest advances in #rheumatology and discussing these with some of the brightest minds in the field. Here are some photos of our team in action and Prof Iain B. McInnes, Vice-Principal and Head of the College of Medical, Veterinary and Life Sciences at the University of Glasgow, presenting key Week 12 efficacy and safety outcomes from the ARGO trial. #MoonLake #MLTX #PsA #HS #IL17F #IL17A 46 Gefällt mir Kommentieren Teilen MoonLake Immunotherapeutics (NASDAQ: MLTX) 4.087 Follower:innen 1 Monat Diesen Beitrag melden For #media #investors: Our Co-founder and CSO Prof. Dr. Kristian Reich along with our medical affairs team, including Senior Director Global Medical Affairs Eva Cullen PhD, Naomi Attar, Sara Souto Pereira and Sónia Guerra Gomes will be attending the EULAR - European Alliance of Associations for Rheumatology Congress 2024 in Vienna, Austria this week. The congress marks a watershed moment for MoonLake with the rheumatology community, as our PsA trial data will be presented to a clinical audience for the first time — Prof Iain B. McInnes, Vice-Principal and Head of the College of Medical, Veterinary and Life Sciences at the University of Glasgow, will present key Week 12 efficacy and safety outcomes from the ARGO trial in the ‘SpA & PsA – Treatment effects and response prediction’ clinical abstract session. Session date and time: Thursday 13th June 10:30 – 12:00 Session room: A2 Expected presentation time: 11:40 -11:50 We hope to see you there! If you are interested in arranging a meeting, please contact us at info@moonlaketx.com. #MoonLake #MLTX #PsA #Congress #Vienna 45 Gefällt mir Kommentieren Teilen MoonLake Immunotherapeutics (NASDAQ: MLTX) 4.087 Follower:innen 1 Monat Bearbeitet Diesen Beitrag melden For #media #investors: Today we announced that MoonLake received positive regulatory feedback from both the FDA and EMA on our Phase 3 program for our Nanobody® in psoriatic arthritis (PsA). This new builds upon the positive regulatory feedback for our Phase 3 VELA program in hidradenitis suppurativa (HS). The new PsA program, named IZAR, will comprise two trials which are anticipated to start in Q4 2024 with primary endpoint readout by the end of 2026. Please read more here: https://lnkd.in/dHzpgjjG #MLTX #MoonLake #Immunotherapeutics #psoriasis #nanobody #IL17F #IL17A #HS #PsA #dermatology 114 Gefällt mir Kommentieren Teilen MoonLake Immunotherapeutics (NASDAQ: MLTX) 4.087 Follower:innen 1 Monat Diesen Beitrag melden LinkedIn: For #media #investors: Our CEO, Jorge Santos da Silva, CFO, Matthias Bodenstedt and Director of IR and BD, Carla Bretes will be attending the Goldman Sachs 45th Annual Global Healthcare Conference taking place from June 10th –13th. Jorge and Matthias will be hosting a fireside chat along on MoonLake’s recent milestones, initiation of Phase 3 trials for HS and its next steps. Contact us at ir@moonlaketx.com if you are interested in meeting. #MoonLake #Nanobodies #MLTX #nanobody #IL17F #IL17A #HS #PsA 30 Gefällt mir Kommentieren Teilen MoonLake Immunotherapeutics (NASDAQ: MLTX) 4.087 Follower:innen 1 Monat Diesen Beitrag melden For #Media #Investors As part of #HSAwarenessWeek, we want to provide an update on our ambition to elevate outcomes for people who suffer from this debilitating disease. Last month, we screened our first patients in our global Phase 3 clinical program for patients with moderate-to-severe hidradenitis suppurativa. This milestone marks a significant step forward in our goal to develop treatments for those in need. Additionally, we will start another Phase 3 program focused on adolescent HS. HS may often begin in the teenage years, yet limited treatment options are available for adolescents, despite the need for timely intervention in a disease such as HS that leads to irreversible tissue damage. By addressing the needs of all HS patients, regardless of age, we hope to advance innovative treatments and improving the quality of life for everyone who is affected by this challenging condition. #HS #MLTX #IL17A #IL17F #IL17 #PsA 90 Gefällt mir Kommentieren Teilen MoonLake Immunotherapeutics (NASDAQ: MLTX) 4.087 Follower:innen 1 Monat Diesen Beitrag melden For #Media #investors As part of our mission to treat #HS, MoonLake is proud to be a Diamond Partner with the non-profit organisation Hidradenitis Suppurativa Foundation, Inc. Like us, they are committed to improving the lives of people affected by HS and run numerous advocacy, education, and research initiatives to increase public awareness for this underdiagnosed disease. In addition to helping fund their important work, our partnership enables us to work closely with HS community to make sure that their needs are addressed as we continue to develop our therapeutic Nanobody®, which is in Phase 3 clinical development. To learn more about HS, visit our page here: https://lnkd.in/g7E2vQnQ #MoonLake #HS #MLTX #IL17A #IL17F #IL17 #PsA Hidradenitis suppurativa https://moonlaketx.com 33 Gefällt mir Kommentieren Teilen View Source13: MoonLake Immunotherapeutics (NASDAQ: MLTX) 4.087 Follower:innen 1 Woche Diesen Beitrag melden For #media #investors: We are proud to be a corporate partner of Group for Research and Assessment of Psoriasis and Psoriatic Arthritis - GRAPPA, whose Annual Meeting and Trainee Symposium will take place in Seattle, US this week. Eva Cullen PhD and Naomi Attar, from our Medical Affairs team, will be attending the meeting and look forward to strengthening our partnership with GRAPPA as we strive toward our shared aims of enhancing research, diagnosis and treatment of psoriatic arthritis. We hope to see you there! If you are interested in arranging a meeting, please contact us at info@moonlaketx.com. #MoonLake #MLTX #PsA #Congress #Conference #HS #IL-17 #Seattle #GRAPPA2024 42 Gefällt mir Kommentieren Teilen MoonLake Immunotherapeutics (NASDAQ: MLTX) 4.087 Follower:innen 3 Wochen Diesen Beitrag melden For #media #investors: Our Medical Affairs team members Eva Cullen PhD, Naomi Attar and Sónia Guerra Gomes are attending IFPA’s 7th World Psoriasis & Psoriatic Arthritis Conference this week in Stockholm. MoonLake clinical trial data is set to be a highlight of the conference — with our abstract one of only six submissions selected by the IFPA scientific committee for an oral presentation. The presentation will report Week 12 multidomain outcomes in the PsA ARGO trial, with Prof. Joseph F Merola MD MMSc (Chair, Dermatology and Professor, Dermatology, Medicine & Rheumatology; UT Southwestern Medical Center, Dallas, TX, USA) as the presenting author. Morning plenary session, June 28, 2024 Main Auditorium, Stockholm Waterfront Congress Center We hope to see you there! If you are interested in arranging a meeting, please contact us at info@moonlaketx.com. #MoonLake #MLTX #PsA 69 Gefällt mir Kommentieren Teilen MoonLake Immunotherapeutics (NASDAQ: MLTX) 4.087 Follower:innen 4 Wochen Diesen Beitrag melden For #media #investors: We were thrilled to win Best Communication Award at the European Mediscience Awards 2024! This achievement would not have been possible without the support, encouragement, and inspiration from the incredible network of the MoonLake Communications Team! It’s also a testament to the power of teamwork and effective communication! Please find below our CFO, Matthias Bodenstedt with Patrícia Marques de Sousa, our Director of Corporate Affairs accompanied by Mary-Jane Elliott, Managing Partner, ICR Consilium, Nina Hossain and Michael White, Head of Life Sciences and Healthcare, HSBC Innovation Banking. Congratulations to all the other award winners and nominees! #MLTX #MoonLake #nanobody #HS #PsA #IL17A #IL17F 119 2 Kommentare Gefällt mir Kommentieren Teilen MoonLake Immunotherapeutics (NASDAQ: MLTX) 4.087 Follower:innen 4 Wochen Diesen Beitrag melden For #media #investors: Our CFO Matthias Bodenstedt is attending the Stifel Europe Healthcare Summit taking place in Lyon on 25-27 June. Contact us at ir@moonlaketx.com if you are interested in meeting. #MoonLake #MLTX #IL17A #IL17F #HS #PsA #nanobody 29 Gefällt mir Kommentieren Teilen MoonLake Immunotherapeutics (NASDAQ: MLTX) 4.087 Follower:innen 1 Monat Diesen Beitrag melden For #media #investors: Thank you EULAR - European Alliance of Associations for Rheumatology Congress for another engaging meeting! We thoroughly enjoyed hearing about the latest advances in #rheumatology and discussing these with some of the brightest minds in the field. Here are some photos of our team in action and Prof Iain B. McInnes, Vice-Principal and Head of the College of Medical, Veterinary and Life Sciences at the University of Glasgow, presenting key Week 12 efficacy and safety outcomes from the ARGO trial. #MoonLake #MLTX #PsA #HS #IL17F #IL17A 46 Gefällt mir Kommentieren Teilen MoonLake Immunotherapeutics (NASDAQ: MLTX) 4.087 Follower:innen 1 Monat Diesen Beitrag melden For #media #investors: Our Co-founder and CSO Prof. Dr. Kristian Reich along with our medical affairs team, including Senior Director Global Medical Affairs Eva Cullen PhD, Naomi Attar, Sara Souto Pereira and Sónia Guerra Gomes will be attending the EULAR - European Alliance of Associations for Rheumatology Congress 2024 in Vienna, Austria this week. The congress marks a watershed moment for MoonLake with the rheumatology community, as our PsA trial data will be presented to a clinical audience for the first time — Prof Iain B. McInnes, Vice-Principal and Head of the College of Medical, Veterinary and Life Sciences at the University of Glasgow, will present key Week 12 efficacy and safety outcomes from the ARGO trial in the ‘SpA & PsA – Treatment effects and response prediction’ clinical abstract session. Session date and time: Thursday 13th June 10:30 – 12:00 Session room: A2 Expected presentation time: 11:40 -11:50 We hope to see you there! If you are interested in arranging a meeting, please contact us at info@moonlaketx.com. #MoonLake #MLTX #PsA #Congress #Vienna 45 Gefällt mir Kommentieren Teilen MoonLake Immunotherapeutics (NASDAQ: MLTX) 4.087 Follower:innen 1 Monat Bearbeitet Diesen Beitrag melden For #media #investors: Today we announced that MoonLake received positive regulatory feedback from both the FDA and EMA on our Phase 3 program for our Nanobody® in psoriatic arthritis (PsA). This new builds upon the positive regulatory feedback for our Phase 3 VELA program in hidradenitis suppurativa (HS). The new PsA program, named IZAR, will comprise two trials which are anticipated to start in Q4 2024 with primary endpoint readout by the end of 2026. Please read more here: https://lnkd.in/dHzpgjjG #MLTX #MoonLake #Immunotherapeutics #psoriasis #nanobody #IL17F #IL17A #HS #PsA #dermatology 114 Gefällt mir Kommentieren Teilen MoonLake Immunotherapeutics (NASDAQ: MLTX) 4.087 Follower:innen 1 Monat Diesen Beitrag melden LinkedIn: For #media #investors: Our CEO, Jorge Santos da Silva, CFO, Matthias Bodenstedt and Director of IR and BD, Carla Bretes will be attending the Goldman Sachs 45th Annual Global Healthcare Conference taking place from June 10th –13th. Jorge and Matthias will be hosting a fireside chat along on MoonLake’s recent milestones, initiation of Phase 3 trials for HS and its next steps. Contact us at ir@moonlaketx.com if you are interested in meeting. #MoonLake #Nanobodies #MLTX #nanobody #IL17F #IL17A #HS #PsA 30 Gefällt mir Kommentieren Teilen MoonLake Immunotherapeutics (NASDAQ: MLTX) 4.087 Follower:innen 1 Monat Diesen Beitrag melden For #Media #Investors As part of #HSAwarenessWeek, we want to provide an update on our ambition to elevate outcomes for people who suffer from this debilitating disease. Last month, we screened our first patients in our global Phase 3 clinical program for patients with moderate-to-severe hidradenitis suppurativa. This milestone marks a significant step forward in our goal to develop treatments for those in need. Additionally, we will start another Phase 3 program focused on adolescent HS. HS may often begin in the teenage years, yet limited treatment options are available for adolescents, despite the need for timely intervention in a disease such as HS that leads to irreversible tissue damage. By addressing the needs of all HS patients, regardless of age, we hope to advance innovative treatments and improving the quality of life for everyone who is affected by this challenging condition. #HS #MLTX #IL17A #IL17F #IL17 #PsA 90 Gefällt mir Kommentieren Teilen MoonLake Immunotherapeutics (NASDAQ: MLTX) 4.087 Follower:innen 1 Monat Diesen Beitrag melden For #Media #investors As part of our mission to treat #HS, MoonLake is proud to be a Diamond Partner with the non-profit organisation Hidradenitis Suppurativa Foundation, Inc. Like us, they are committed to improving the lives of people affected by HS and run numerous advocacy, education, and research initiatives to increase public awareness for this underdiagnosed disease. In addition to helping fund their important work, our partnership enables us to work closely with HS community to make sure that their needs are addressed as we continue to develop our therapeutic Nanobody®, which is in Phase 3 clinical development. To learn more about HS, visit our page here: https://lnkd.in/g7E2vQnQ #MoonLake #HS #MLTX #IL17A #IL17F #IL17 #PsA Hidradenitis suppurativa https://moonlaketx.com 33 Gefällt mir Kommentieren Teilen View Source14: MoonLake Immunotherapeutics (NASDAQ: MLTX) 4.087 Follower:innen 1 Woche Diesen Beitrag melden For #media #investors: We are proud to be a corporate partner of Group for Research and Assessment of Psoriasis and Psoriatic Arthritis - GRAPPA, whose Annual Meeting and Trainee Symposium will take place in Seattle, US this week. Eva Cullen PhD and Naomi Attar, from our Medical Affairs team, will be attending the meeting and look forward to strengthening our partnership with GRAPPA as we strive toward our shared aims of enhancing research, diagnosis and treatment of psoriatic arthritis. We hope to see you there! If you are interested in arranging a meeting, please contact us at info@moonlaketx.com. #MoonLake #MLTX #PsA #Congress #Conference #HS #IL-17 #Seattle #GRAPPA2024 42 Gefällt mir Kommentieren Teilen MoonLake Immunotherapeutics (NASDAQ: MLTX) 4.087 Follower:innen 3 Wochen Diesen Beitrag melden For #media #investors: Our Medical Affairs team members Eva Cullen PhD, Naomi Attar and Sónia Guerra Gomes are attending IFPA’s 7th World Psoriasis & Psoriatic Arthritis Conference this week in Stockholm. MoonLake clinical trial data is set to be a highlight of the conference — with our abstract one of only six submissions selected by the IFPA scientific committee for an oral presentation. The presentation will report Week 12 multidomain outcomes in the PsA ARGO trial, with Prof. Joseph F Merola MD MMSc (Chair, Dermatology and Professor, Dermatology, Medicine & Rheumatology; UT Southwestern Medical Center, Dallas, TX, USA) as the presenting author. Morning plenary session, June 28, 2024 Main Auditorium, Stockholm Waterfront Congress Center We hope to see you there! If you are interested in arranging a meeting, please contact us at info@moonlaketx.com. #MoonLake #MLTX #PsA 69 Gefällt mir Kommentieren Teilen MoonLake Immunotherapeutics (NASDAQ: MLTX) 4.087 Follower:innen 4 Wochen Diesen Beitrag melden For #media #investors: We were thrilled to win Best Communication Award at the European Mediscience Awards 2024! This achievement would not have been possible without the support, encouragement, and inspiration from the incredible network of the MoonLake Communications Team! It’s also a testament to the power of teamwork and effective communication! Please find below our CFO, Matthias Bodenstedt with Patrícia Marques de Sousa, our Director of Corporate Affairs accompanied by Mary-Jane Elliott, Managing Partner, ICR Consilium, Nina Hossain and Michael White, Head of Life Sciences and Healthcare, HSBC Innovation Banking. Congratulations to all the other award winners and nominees! #MLTX #MoonLake #nanobody #HS #PsA #IL17A #IL17F 119 2 Kommentare Gefällt mir Kommentieren Teilen MoonLake Immunotherapeutics (NASDAQ: MLTX) 4.087 Follower:innen 4 Wochen Diesen Beitrag melden For #media #investors: Our CFO Matthias Bodenstedt is attending the Stifel Europe Healthcare Summit taking place in Lyon on 25-27 June. Contact us at ir@moonlaketx.com if you are interested in meeting. #MoonLake #MLTX #IL17A #IL17F #HS #PsA #nanobody 29 Gefällt mir Kommentieren Teilen MoonLake Immunotherapeutics (NASDAQ: MLTX) 4.087 Follower:innen 1 Monat Diesen Beitrag melden For #media #investors: Thank you EULAR - European Alliance of Associations for Rheumatology Congress for another engaging meeting! We thoroughly enjoyed hearing about the latest advances in #rheumatology and discussing these with some of the brightest minds in the field. Here are some photos of our team in action and Prof Iain B. McInnes, Vice-Principal and Head of the College of Medical, Veterinary and Life Sciences at the University of Glasgow, presenting key Week 12 efficacy and safety outcomes from the ARGO trial. #MoonLake #MLTX #PsA #HS #IL17F #IL17A 46 Gefällt mir Kommentieren Teilen MoonLake Immunotherapeutics (NASDAQ: MLTX) 4.087 Follower:innen 1 Monat Diesen Beitrag melden For #media #investors: Our Co-founder and CSO Prof. Dr. Kristian Reich along with our medical affairs team, including Senior Director Global Medical Affairs Eva Cullen PhD, Naomi Attar, Sara Souto Pereira and Sónia Guerra Gomes will be attending the EULAR - European Alliance of Associations for Rheumatology Congress 2024 in Vienna, Austria this week. The congress marks a watershed moment for MoonLake with the rheumatology community, as our PsA trial data will be presented to a clinical audience for the first time — Prof Iain B. McInnes, Vice-Principal and Head of the College of Medical, Veterinary and Life Sciences at the University of Glasgow, will present key Week 12 efficacy and safety outcomes from the ARGO trial in the ‘SpA & PsA – Treatment effects and response prediction’ clinical abstract session. Session date and time: Thursday 13th June 10:30 – 12:00 Session room: A2 Expected presentation time: 11:40 -11:50 We hope to see you there! If you are interested in arranging a meeting, please contact us at info@moonlaketx.com. #MoonLake #MLTX #PsA #Congress #Vienna 45 Gefällt mir Kommentieren Teilen MoonLake Immunotherapeutics (NASDAQ: MLTX) 4.087 Follower:innen 1 Monat Bearbeitet Diesen Beitrag melden For #media #investors: Today we announced that MoonLake received positive regulatory feedback from both the FDA and EMA on our Phase 3 program for our Nanobody® in psoriatic arthritis (PsA). This new builds upon the positive regulatory feedback for our Phase 3 VELA program in hidradenitis suppurativa (HS). The new PsA program, named IZAR, will comprise two trials which are anticipated to start in Q4 2024 with primary endpoint readout by the end of 2026. Please read more here: https://lnkd.in/dHzpgjjG #MLTX #MoonLake #Immunotherapeutics #psoriasis #nanobody #IL17F #IL17A #HS #PsA #dermatology 114 Gefällt mir Kommentieren Teilen MoonLake Immunotherapeutics (NASDAQ: MLTX) 4.087 Follower:innen 1 Monat Diesen Beitrag melden LinkedIn: For #media #investors: Our CEO, Jorge Santos da Silva, CFO, Matthias Bodenstedt and Director of IR and BD, Carla Bretes will be attending the Goldman Sachs 45th Annual Global Healthcare Conference taking place from June 10th –13th. Jorge and Matthias will be hosting a fireside chat along on MoonLake’s recent milestones, initiation of Phase 3 trials for HS and its next steps. Contact us at ir@moonlaketx.com if you are interested in meeting. #MoonLake #Nanobodies #MLTX #nanobody #IL17F #IL17A #HS #PsA 30 Gefällt mir Kommentieren Teilen MoonLake Immunotherapeutics (NASDAQ: MLTX) 4.087 Follower:innen 1 Monat Diesen Beitrag melden For #Media #Investors As part of #HSAwarenessWeek, we want to provide an update on our ambition to elevate outcomes for people who suffer from this debilitating disease. Last month, we screened our first patients in our global Phase 3 clinical program for patients with moderate-to-severe hidradenitis suppurativa. This milestone marks a significant step forward in our goal to develop treatments for those in need. Additionally, we will start another Phase 3 program focused on adolescent HS. HS may often begin in the teenage years, yet limited treatment options are available for adolescents, despite the need for timely intervention in a disease such as HS that leads to irreversible tissue damage. By addressing the needs of all HS patients, regardless of age, we hope to advance innovative treatments and improving the quality of life for everyone who is affected by this challenging condition. #HS #MLTX #IL17A #IL17F #IL17 #PsA 90 Gefällt mir Kommentieren Teilen MoonLake Immunotherapeutics (NASDAQ: MLTX) 4.087 Follower:innen 1 Monat Diesen Beitrag melden For #Media #investors As part of our mission to treat #HS, MoonLake is proud to be a Diamond Partner with the non-profit organisation Hidradenitis Suppurativa Foundation, Inc. Like us, they are committed to improving the lives of people affected by HS and run numerous advocacy, education, and research initiatives to increase public awareness for this underdiagnosed disease. In addition to helping fund their important work, our partnership enables us to work closely with HS community to make sure that their needs are addressed as we continue to develop our therapeutic Nanobody®, which is in Phase 3 clinical development. To learn more about HS, visit our page here: https://lnkd.in/g7E2vQnQ #MoonLake #HS #MLTX #IL17A #IL17F #IL17 #PsA Hidradenitis suppurativa https://moonlaketx.com 33 Gefällt mir Kommentieren Teilen View Source15: MoonLake Immunotherapeutics (NASDAQ: MLTX) 4.087 Follower:innen 1 Woche Diesen Beitrag melden For #media #investors: We are proud to be a corporate partner of Group for Research and Assessment of Psoriasis and Psoriatic Arthritis - GRAPPA, whose Annual Meeting and Trainee Symposium will take place in Seattle, US this week. Eva Cullen PhD and Naomi Attar, from our Medical Affairs team, will be attending the meeting and look forward to strengthening our partnership with GRAPPA as we strive toward our shared aims of enhancing research, diagnosis and treatment of psoriatic arthritis. We hope to see you there! If you are interested in arranging a meeting, please contact us at info@moonlaketx.com. #MoonLake #MLTX #PsA #Congress #Conference #HS #IL-17 #Seattle #GRAPPA2024 42 Gefällt mir Kommentieren Teilen MoonLake Immunotherapeutics (NASDAQ: MLTX) 4.087 Follower:innen 3 Wochen Diesen Beitrag melden For #media #investors: Our Medical Affairs team members Eva Cullen PhD, Naomi Attar and Sónia Guerra Gomes are attending IFPA’s 7th World Psoriasis & Psoriatic Arthritis Conference this week in Stockholm. MoonLake clinical trial data is set to be a highlight of the conference — with our abstract one of only six submissions selected by the IFPA scientific committee for an oral presentation. The presentation will report Week 12 multidomain outcomes in the PsA ARGO trial, with Prof. Joseph F Merola MD MMSc (Chair, Dermatology and Professor, Dermatology, Medicine & Rheumatology; UT Southwestern Medical Center, Dallas, TX, USA) as the presenting author. Morning plenary session, June 28, 2024 Main Auditorium, Stockholm Waterfront Congress Center We hope to see you there! If you are interested in arranging a meeting, please contact us at info@moonlaketx.com. #MoonLake #MLTX #PsA 69 Gefällt mir Kommentieren Teilen MoonLake Immunotherapeutics (NASDAQ: MLTX) 4.087 Follower:innen 4 Wochen Diesen Beitrag melden For #media #investors: We were thrilled to win Best Communication Award at the European Mediscience Awards 2024! This achievement would not have been possible without the support, encouragement, and inspiration from the incredible network of the MoonLake Communications Team! It’s also a testament to the power of teamwork and effective communication! Please find below our CFO, Matthias Bodenstedt with Patrícia Marques de Sousa, our Director of Corporate Affairs accompanied by Mary-Jane Elliott, Managing Partner, ICR Consilium, Nina Hossain and Michael White, Head of Life Sciences and Healthcare, HSBC Innovation Banking. Congratulations to all the other award winners and nominees! #MLTX #MoonLake #nanobody #HS #PsA #IL17A #IL17F 119 2 Kommentare Gefällt mir Kommentieren Teilen MoonLake Immunotherapeutics (NASDAQ: MLTX) 4.087 Follower:innen 4 Wochen Diesen Beitrag melden For #media #investors: Our CFO Matthias Bodenstedt is attending the Stifel Europe Healthcare Summit taking place in Lyon on 25-27 June. Contact us at ir@moonlaketx.com if you are interested in meeting. #MoonLake #MLTX #IL17A #IL17F #HS #PsA #nanobody 29 Gefällt mir Kommentieren Teilen MoonLake Immunotherapeutics (NASDAQ: MLTX) 4.087 Follower:innen 1 Monat Diesen Beitrag melden For #media #investors: Thank you EULAR - European Alliance of Associations for Rheumatology Congress for another engaging meeting! We thoroughly enjoyed hearing about the latest advances in #rheumatology and discussing these with some of the brightest minds in the field. Here are some photos of our team in action and Prof Iain B. McInnes, Vice-Principal and Head of the College of Medical, Veterinary and Life Sciences at the University of Glasgow, presenting key Week 12 efficacy and safety outcomes from the ARGO trial. #MoonLake #MLTX #PsA #HS #IL17F #IL17A 46 Gefällt mir Kommentieren Teilen MoonLake Immunotherapeutics (NASDAQ: MLTX) 4.087 Follower:innen 1 Monat Diesen Beitrag melden For #media #investors: Our Co-founder and CSO Prof. Dr. Kristian Reich along with our medical affairs team, including Senior Director Global Medical Affairs Eva Cullen PhD, Naomi Attar, Sara Souto Pereira and Sónia Guerra Gomes will be attending the EULAR - European Alliance of Associations for Rheumatology Congress 2024 in Vienna, Austria this week. The congress marks a watershed moment for MoonLake with the rheumatology community, as our PsA trial data will be presented to a clinical audience for the first time — Prof Iain B. McInnes, Vice-Principal and Head of the College of Medical, Veterinary and Life Sciences at the University of Glasgow, will present key Week 12 efficacy and safety outcomes from the ARGO trial in the ‘SpA & PsA – Treatment effects and response prediction’ clinical abstract session. Session date and time: Thursday 13th June 10:30 – 12:00 Session room: A2 Expected presentation time: 11:40 -11:50 We hope to see you there! If you are interested in arranging a meeting, please contact us at info@moonlaketx.com. #MoonLake #MLTX #PsA #Congress #Vienna 45 Gefällt mir Kommentieren Teilen MoonLake Immunotherapeutics (NASDAQ: MLTX) 4.087 Follower:innen 1 Monat Bearbeitet Diesen Beitrag melden For #media #investors: Today we announced that MoonLake received positive regulatory feedback from both the FDA and EMA on our Phase 3 program for our Nanobody® in psoriatic arthritis (PsA). This new builds upon the positive regulatory feedback for our Phase 3 VELA program in hidradenitis suppurativa (HS). The new PsA program, named IZAR, will comprise two trials which are anticipated to start in Q4 2024 with primary endpoint readout by the end of 2026. Please read more here: https://lnkd.in/dHzpgjjG #MLTX #MoonLake #Immunotherapeutics #psoriasis #nanobody #IL17F #IL17A #HS #PsA #dermatology 114 Gefällt mir Kommentieren Teilen MoonLake Immunotherapeutics (NASDAQ: MLTX) 4.087 Follower:innen 1 Monat Diesen Beitrag melden LinkedIn: For #media #investors: Our CEO, Jorge Santos da Silva, CFO, Matthias Bodenstedt and Director of IR and BD, Carla Bretes will be attending the Goldman Sachs 45th Annual Global Healthcare Conference taking place from June 10th –13th. Jorge and Matthias will be hosting a fireside chat along on MoonLake’s recent milestones, initiation of Phase 3 trials for HS and its next steps. Contact us at ir@moonlaketx.com if you are interested in meeting. #MoonLake #Nanobodies #MLTX #nanobody #IL17F #IL17A #HS #PsA 30 Gefällt mir Kommentieren Teilen MoonLake Immunotherapeutics (NASDAQ: MLTX) 4.087 Follower:innen 1 Monat Diesen Beitrag melden For #Media #Investors As part of #HSAwarenessWeek, we want to provide an update on our ambition to elevate outcomes for people who suffer from this debilitating disease. Last month, we screened our first patients in our global Phase 3 clinical program for patients with moderate-to-severe hidradenitis suppurativa. This milestone marks a significant step forward in our goal to develop treatments for those in need. Additionally, we will start another Phase 3 program focused on adolescent HS. HS may often begin in the teenage years, yet limited treatment options are available for adolescents, despite the need for timely intervention in a disease such as HS that leads to irreversible tissue damage. By addressing the needs of all HS patients, regardless of age, we hope to advance innovative treatments and improving the quality of life for everyone who is affected by this challenging condition. #HS #MLTX #IL17A #IL17F #IL17 #PsA 90 Gefällt mir Kommentieren Teilen MoonLake Immunotherapeutics (NASDAQ: MLTX) 4.087 Follower:innen 1 Monat Diesen Beitrag melden For #Media #investors As part of our mission to treat #HS, MoonLake is proud to be a Diamond Partner with the non-profit organisation Hidradenitis Suppurativa Foundation, Inc. Like us, they are committed to improving the lives of people affected by HS and run numerous advocacy, education, and research initiatives to increase public awareness for this underdiagnosed disease. In addition to helping fund their important work, our partnership enables us to work closely with HS community to make sure that their needs are addressed as we continue to develop our therapeutic Nanobody®, which is in Phase 3 clinical development. To learn more about HS, visit our page here: https://lnkd.in/g7E2vQnQ #MoonLake #HS #MLTX #IL17A #IL17F #IL17 #PsA Hidradenitis suppurativa https://moonlaketx.com 33 Gefällt mir Kommentieren Teilen View Source16: MoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditions View Source